EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

A 2024 Update on Menin Inhibitors. A New Class of Target Agents against KMT2A-Rearranged and NPM1-Mutated Acute Myeloid Leukemia

Anna Candoni iD, Gabriele Coppola

Hematology Reports · 18.04.2024 · 16 (2) · 244-254

DOI: 10.3390/hematolrep16020024 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Hematology Reports, online erschienen am 18.04.2024. Verfasst von Anna Candoni und 1 weiteren Autor:innen. Beteiligte Einrichtung: Section of Haematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Via del Pozzo 71, 41123 Modena, Italy. Die Arbeit wurde bisher 85-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Menin inhibitors are new and promising agents currently in clinical development that target the HOX/MEIS1 transcriptional program which is critical for leukemogenesis in histone-lysine N-methyltransferase 2A-rearranged (KMT2Ar) and in NPM1-mutated (NPM1mut) acute leukemias. The mechanism of action of this new class of agents is based on the disruption of the menin–KMT2A complex (consisting of chromatin remodeling proteins), leading to the differentiation and apoptosis of AML cells expressing KMT2A or with mutated NPM1. To date, this new class of drugs has been tested in phase I and II clinical trials, both alone and in combination with synergistic drugs showing promising results in terms of response rates and safety in heavily pre-treated acute leukemia patients. In this brief review, we summarize the key findings on menin inhibitors, focusing on the mechanism of action and preliminary clinical data on the treatment of acute myeloid leukemia with this promising new class of agents, particularly revumenib and ziftomenib.

Schlagwörter

Stichwörter der Autor:innen

HOX genesKMT2ANPM1acute leukemiameninmenin inhibitorsrevumenibziftomenib

Autor:innen und Institutionen

  • Section of Haematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Via del Pozzo 71, 41123 Modena, Italy.

ORCID-Profile: Anna Candoni

Zitieren

APA

Candoni, A., & Coppola, G. (2024). A 2024 Update on Menin Inhibitors. A New Class of Target Agents against KMT2A-Rearranged and NPM1-Mutated Acute Myeloid Leukemia. Hematology Reports, 16(2), 244-254. https://doi.org/10.3390/hematolrep16020024

Vancouver

Candoni A, Coppola G. A 2024 Update on Menin Inhibitors. A New Class of Target Agents against KMT2A-Rearranged and NPM1-Mutated Acute Myeloid Leukemia. Hematology Reports. 2024;16(2):244-254. doi:10.3390/hematolrep16020024

BibTeX
@article{Candoni2024,
  author = {Candoni, Anna and Coppola, Gabriele},
  title = {A 2024 Update on Menin Inhibitors. A New Class of Target Agents against KMT2A-Rearranged and NPM1-Mutated Acute Myeloid Leukemia},
  journal = {Hematology Reports},
  year = {2024},
  volume = {16},
  number = {2},
  pages = {244--254},
  doi = {10.3390/hematolrep16020024}
}
Kostenlos starten →